Systemic lupus erythematosus (SLE) is an autoimmune disorder affecting multiple organ systems. It is characterized by the presence of autoantibodies reactive against various self-antigens. Susceptibility to SLE is found to be associated with many major histocompatibility complex (MHC) and non-MHC genes, one of which is APO-1/Fas gene, which is present on chromosome 10 in humans. The APO-1/Fas promoter contains consensus sequences for binding of several transcription factors that affect the intensity of Fas expression in cells. The mutations in the APO-1/Fas promoter are associated with risk and severity in various autoimmune diseases and other malignancies. The APO-1/Fas receptor is expressed by many cell types. Two forms of APO-1/Fas protein that are involved in regulation of apoptosis have been identified. Fas receptor-mediated apoptosis plays a physiological and pathological role in killing of infected cell targets. In this review, we have focused on APO-1/Fas gene structure, promoter variants and its association with SLE and other autoimmune diseases. Functional aspects of Fas receptor in apoptosis are also discussed.
Introduction

Systemic lupus erythematosus (SLE) is
Organization of the human APO-1/Fas gene
The human APO-1/Fas gene has been mapped to chromosome 10q24.1 [7] or 10q23 [8] and spans Figure 1 ]. [6, 9] The APO-1/Fas gene is the longest gene of its family of Japanese SLE patients with 297 C/416 G haplotype in APO-1/Fas gene has also been reported. [12] [13] [14] [15] [16] Studies on other autoimmune diseases revealed the association of Fas -670 G . A polymorphism with disease susceptibility in multiple sclerosis (MS), [17, 18] autoimmune hepatitis [19] and systemic sclerosis. [20] Contradictory results
were obtained in the study of rheumatoid arthritis (RA) [14] and Sjögren's syndrome (SS). [21, 22] No such association has been found in organ-specific autoimmune diseases like Hashimoto's thyroiditis, [23] Grave's disease [23] and inflammatory bowel disease. [12] It is also reported that the Fas has been associated with the loss of regulation of B-lymphocytes, which predisposes to SLE. [27] [28] [29] [30] Gene upregulation precedes apoptosis. APO-1/Fas expression on cells can be induced by cytokines like IFN-g and TNF-a. [31] Increased expression of mFas has been reported in SLE, [32] MS, [33] chronic adult t-cell leukemia, [34] sarcoidosis, [35] hepatitis B [36] and hepatitis C [37] infections.
sFas levels in the serum are a marker for evaluating SLE disease activity. sFas is present at a high concentration in about 60% of lupus patients. Frequency of positive serum sFas is much greater with high SLE disease activity index scores than with low scores. Improvement in the clinical status of a patient after corticosteroid therapy results in decrease in sFas levels in the serum. [38, 39] The levels of sFas were also found to be higher in case of scleroderma and sarcoidosis with the 2670 AA, intermediate with the 2670 AG and lowest with the 2670 GG genotypes. [20, 35] Patients with active Behcet's disease, [40] silicosis [41] and non-hematopoietic malignancies [42] also have high sFas levels.
Other systemic lupus erythematosus susceptibility genes
Multiple factors contribute to the development of an autoimmune disease. These can be immunological, IL1B at 2q13 for SLE. [43] Susceptibility to SLE also [9] involves class II MHC gene polymorphism. It is found to be commonly associated with HLA-DR2 and HLA-DR3. These alleles confer two-fold to five-fold risk for lupus. Certain complement deficiencies (C1q, C2, C4a) have been strongly related to the development of SLE.
Polymorphisms of genes encoding TCR, FcgR, cytokines and cytokine receptors have also been studied for their possible involvement in autoreactivity.
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Future prospects
There is a need to explore genetic association in the diverse populations of India. Population studies revealed that each population holds a mutational pool in which most mutations or polymorphisms have undetectable effects on an individual, but, in combination with other alleles, it may promote or prevent from autoimmune diseases. [44] Lack of validated biomarkers for disease activity has been a barrier to drug discovery. Candidate biomarker approach is based on the study of known factors that are thought to be involved in disease pathogenesis to identify biomarkers. [45] It would be of great interest to study APO-1/Fas promoter, complement receptors, cytokines genes and their promoters and signal transducer molecules for understanding the immunopathogenesis of autoimmune diseases. This will also help to evaluate genetic and racial/ethnic influences on susceptibility, severity and treatment response in autoimmune diseases.
Protein profiling using proteomic techniques like immobilized antibody array, surface-enhanced laser desorption/ionization-time of flight-mass spectrometry and matrix-assisted laser desorption/ionization-time of flight-mass spectrometry is high throughput and does not rely on the predetermined notions of disease pathogenesis. [45, 46] It has the potential of identifying novel, unexpected biomarkers that can be incorporated into multivariate prediction models. These validated proteins can then be used as input variables for drug designing.
Identification of more biomarkers will definitely increase the strength of immunogenetic analysis and aid in early diagnosis of patients, severity, detecting remission and targeting the high-risk population to reduce disease acquisition.
